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index, and the volume receiving 10 and 12 Gy indicating risk 
of radionecrosis. 
Results: All plans were judged clinically acceptable, but 
differences were observed in the dosimetric parameters. 
MIDCA achieved conformal plans (CI = 0.66 ± 0.07) with steep 
dose fall-off (GI = 4.47 ± 1.57), a V12 of 35.56 ± 26.41 cc and 
a V10 of 49.03 ± 38.10 cc. The VMAT plans had comparable 
conformity (0.67 ± 0.12) than MIDCA, worse GI (7.11 ± 3.12) 
and higher V10 (67.93 ± 55.93 cc) and V12 (46.34 ± 35.92 cc). 
The brain metastases software tool generated plans with 
similar CI (0.65 ± 0.08) then the two established treatment 
techniques while improving the GI (3.94 ± 1.42) and managing 
comparable V10 (48.47 ± 35.93 cc) and V12 (36.30 ± 27.09 cc) 
compared to MIDCA. 
Conclusions: Our results suggest that the automated brain 
metastases planning algorithm can achieve similar conformity 
and low dose spread compared to multi-isocenter DCA while 
increasing efficiency in both treatment planning and delivery 
due to the use of a single-isocenter approach. In terms of 
efficiency, VMAT radiosurgery was already likely to replace 
the multi-isocenter DCA technique for multiple lesions at the 
cost of increased low dose spread. Comparable efficiency was 
found with the new algorithm while improved dose gradient 
was observed suggesting that this novel software offers the 
best of both world (i.e. efficient single-isocenter DCA 
delivery). 
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Purpose/Objective: In our clinic, the treatment technique of 
choice for the majority of patients is Volumetric Arc Therapy. 
At present, paediatric medulloblastoma patients undergoing 
cranial spinal radiotherapy will be offered proton therapy 
elsewhere. Sometimes, due to bad prognoses and physical 
shape of the patient, the patient is treated locally with 
classical 3D-CRT photon fields. Overlapping posterior fields 
induces high dose maximums and the dose distribution will be 
sensitive to patient positioning. Moreover, this technique is 
prone to high heart doses and inhomogeneous target 
coverage. This study compares VMAT plans with classical 3D-
CRT plans while comparing the risk for mortality attributable 
to secondary cancer and heart toxicity using the Life Years 
Lost-principle (LYL1) as well as the risk for hematologic 
effects2. Furthermore, the VMAT plans can be optimized in a 
fashion that the dose distribution will be less sensitive to 
patient positioning and the benefit of such an approach will 
be assessed. 
Materials and Methods: Five patients were treated with the 
3D-CRT cranial spinal technique. On those patients all OAR 
were retrospectively delineated including the bone producing 
bone marrow. The VMAT plans consists of fields that are 
deliberately field overlapping, ranging from 1 to 4 cm. The 
total dose was 36 Gy in 20 fractions. The robustness of the 
dose distribution towards patient positioning errors was 
tested by moving the isocentres in the treatment plan by 5 
mm in the cranial-caudal direction. The LYL estimates were 
calculated and compared for lung and heart. The acute 
haematological toxicity was investigated by calculating the 
V3Gy of the red marrow (trombocytes) and the V2Gy 
(leukocytes), V3Gy (hæmoglobin) to the total body. 
Results: As a result, the dose max for both planning 
techniques changes according to table 1. The LYL for lungs 
increases with a factor 1.5 to 3 and the LYL for myocardial 
infarction decreases with a factor 0.5 to 1.0 when using 
VMAT. The V3Gy of the bone marrow and V3Gy, V2Gy of the body 
increases with a factor 2 when using VMAT. 
Conclusions: The VMAT technique provides a more robust 
dose distribution. The LYL principle can be used as a measure 
to compare plans and to re-optimize the dose distribution. 
The LYL estimates are intrinsically uncertain due to the 
limited knowledge of second cancer dose-response and the 
incidence profile across attained age, and the results should 
be interpreted in this context. The VMAT technique will 
induce a higher risk of acute Anaemia, leukopaenia and 
Thrombocytopaenia, but can be controlled when the patient 
is monitored daily. 
1 Brodin NP et al, Life Years Lost-Comparing potentially fatal 
late complications after radiotherapy for pediatric 
medulloblastoma on a common scale, Cancer, 2012 Nov 
1;118(21):5432-40 
2 Petersson K et al, Haematological toxicity in adult patients 
receiving craniospinal irrdation – indication of a dose-bath 
effect, Radioth and Onc, 2014 Apr;111(1):47-51 
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Purpose/Objective: Varian RapidPlan™ knowledge-based 
planning software is designed to increase consistency and 
improve efficiency in treatment planning. The aim of this 
study was to compare the quality of plans produced using 
RapidPlan with those produced following local standard 
planning procedures for prostate treatments.  
Materials and Methods: A dose prediction model was trained 
using clinical treatment plans for 35 prostate patients 
previously treated with 37 fractions of 5-field IMRT. A high-
dose PTV (prostate + 0.5cm/0cm posterior margin) was 
planned to 78Gy, with additional PTVs treated to 71Gy 
(prostate + 1.0cm/0.6cm) and 60Gy (seminal vesicles + 
1.0cm) using Varian Eclipse v13.5. 10 additional patients 
previously planned using local clinical procedures were then 
replanned using the RapidPlan model to predict DVHs and 
thereby generate patient-specific initial plan optimization 
objectives. Priorities for minimum target dose objectives 
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were fixed to ensure adequate target coverage; all other 
priorities were automatically set by RapidPlan. Following 
plan optimization each plan was assessed against clinical 
dose constraints and if necessary, objective priorities were 
adjusted and optimization repeated until a clinically 
acceptable plan was achieved.  
Results: Acceptable plans were produced using the initial 
objectives without further planner intervention for 4 out of 
10 patients. A maximum of 2 iterations of priority 
adjustments was required to optimize plans for the remaining 
patients. Mean dose statistics for the final plans are shown in 
Table 1. The RapidPlan plans showed a significant (P<0.05) 
increase in target coverage (measure by the D99%) for all PTVs 
and a significant reduction in mean bladder and rectal doses. 
This was largely due to a reduction in OAR DVHs at low to 
moderate doses, as the maximum rectal and bladder doses 
were slightly increased. MUs were generally higher than for 
clinical plans, but the difference was not found to be 
significant.  
Table 1 Summary of average (range) dose statistics and MUs 
comparing RapidPlan with original treatment plans. 
 
 
Conclusions: With a model based on local plan data, it was 
possible to efficiently produce clinically acceptable prostate 
plans using RapidPlan. OAR doses were generally reduced and 
target coverage increased; target minimum dose priorities 
may need to be adjusted to optimize the balance between 
target coverage and OAR maximum doses. This could improve 
efficiency by reducing the proportion of patients for whom 
additional planner intervention is required. Our first clinical 
plan produced using RapidPlan has been clinically approved, 
with the patient due to start treatment in December 2014.  
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Purpose/Objective: The aim was to investigate the 
differences between Ray-Tracing and Monte Carlo dose 
calculation algorithm for treatment of non-small cell lung 
cancer (NSCLC) patients using Cyberknife (Accuray, 
Sunnyvale, US). Special attention was paid on physical and 
biological dose and tumor control probability (TCP) 
differences. 
Materials and Methods: Twenty six patients (with a total of 
30 lesions) in early stage NSCLC were administered 
stereotactic ablative radiotherapy (SABR) in our institution 
using Cyberknife. For all patients clinical target volume (CTV) 
to planning target volume (PTV) margin varied between 2 and 
5 mm and was tracking-method dependant. Risk-adapted 
dose prescription scheme was used for several patients who 
were not suitable for the intended 3 times 20 Gy. 
Retrospective dose calculation with Monte Carlo (MC) was 
performed on plans previously calculated with the Ray-
Tracing (RT) algorithm. Monitor unit and beam orientation 
were preserved. Biologically relevant dose differences were 
analyzed using CTV's mean dose and generalized equivalent 
uniform dose (gEUD) using an a value of -10, to give higher 
importance to lower doses. Physical dose differences were 
collected combined with the corresponding biological 
equivalent dose (BED10) using the method suggested by (Ohri 
& al. IJROBP 2012). Furthermore tumor control differences 
were assessed using a TCP model established for lung SBRT 
and taking into account the size of the target. Differences 
between the two algorithm were tested using a paired t-test 
with a significance level of p<0.05. 
Results: CTV volume and spherically approximated diameter 
were on average 20.7 cc (sd = 19.6 cc) and 3 cm (sd = 1.2 
cm). Focusing on physical dose differences (RT vs. MC) of the 
CTV, average mean dose and gEUD were 62.6 (9.4) vs. 48.5 
(8.1) and 61.4 (10.3) vs. 41.1 (10.5) Gy. Physical dose 
differences (mean/gEUD) higher than 20% were found for 50 
% / 57% of the patients. Corresponding biological dose 
differences were on average 194 (50) vs. 127 (36) and 188 
(53) vs. 99 (40) Gy respectively for mean and gEUD doses. 
This lead in 85% of the cases more than 10Gy BED decrease. 
Associated TCP were on average 92 (3) % vs. 97(5) % and 
94(5) % vs. 86(11) %. Nearly half of the patient population 
(46.7%) presented gEUD-based TCP differences higher than 
10% vs. 2 patients (6.7%) for the mean dose-based TCP. All of 
the differences were statistically significant (p<0.001) in 
every aspect.  
Summary of the result are presented in Figure 1 using a 
boxplot representation. 
 
 
Figure 1. Mean dose vs. gEUD to describe a) physical dose, b) 
biological equivalent dose and c) tumor control probability 
differences between Ray-Tracing and Monte Carlo algorithm 
 
Conclusions: Dose calculation differences between RT and 
MC algorithm could lead into severe differences in physical 
and biological doses which could dramatically worsened the 
TCP. Clinical follow-up is necessary to confirm the finding. 
 
 
